AI Pharmaceutical Leader Storming into Hong Kong Stocks! Insilico Medicine Passes Hearing, Hong Kong "Patience Capital" Bets on the Future
On December 14, 2025, AI pharmaceutical leading company Insilico Medicine passed the listing hearing with the Hong Kong Stock Exchange, just one step away from being listed on the main board of Hong Kong stocks, with Morgan Stanley, CICC, and GF Securities serving as joint sponsors.
As the world's first biotech company to advance AI-developed drugs to clinical trials, its listing process is crucial for the capital value of the entire AI pharmaceutical sector. Notably, one of the investors, Hong Kong Investment Management Company (HKIM), represents Hong Kong "Patience Capital" and is deeply investing in cutting-edge biotechnology, providing long-term financial support for the company.
Insilico Medicine was established in 2014, focusing on AI-driven innovative drug development. Its self-developed generative AI platform Pharma.AI covers the entire process from target discovery to clinical validation, currently having over 20 clinical or IND-stage research pipelines, focusing on unmet medical needs in fields such as cancer and fibrosis.
The core candidate drug ISM001-055 (for the treatment of idiopathic pulmonary fibrosis) is the fastest progressing AI drug in the world, having completed Phase IIa clinical trials and received breakthrough therapy designation from the National Medical Products Administration. It is set to advance to Phase IIb/III trials, potentially becoming the world's first AI-designed drug to enter Phase III clinical trials.
New drug development is extremely costly, and Insilico Medicine has completed 11 rounds of financing to date, attracting well-known institutions such as Temasek and Warburg Pincus. The E round of financing in 2025 raised $123 million (exceeding the target), with a post-investment valuation reaching $1.33 billion.
HKIM, as the wholly-owned "Patience Capital" platform of the Hong Kong Special Administrative Region government, does not pursue short-term returns but focuses on accompanying the long-term growth of enterprises. Its CEO, Chen Jiaqi, has stated that Hong Kong can gather talent, innovation, and financial resources, and HKIM will leverage this advantage to provide long-term capital support for high-quality innovation and technology enterprises.
Insilico Medicine's push into Hong Kong stocks reflects the maturity of Hong Kong's biotechnology industry ecosystem and capital empowerment system. HKIM is strategically focusing on the AI pharmaceutical sector, not only filling the long-term funding gap for enterprises but also facilitating their connection to Hong Kong's industrial resources — currently, Insilico Medicine has established AI technology licensing collaborations with 9 of the top 20 global pharmaceutical companies through Hong Kong platforms, reinforcing Hong Kong's position as a hub for biotechnology and global capital connectivity. $BTC #BinanceABCs
